STEP™ Technology
Advances in cell culture technologies, media developments and expression plasmid technology have resulted in significant improvements in protein yield on mammalian cells over the last decades. For many proteins yield is however still an area requiring improvement.
High protein producing, stable cell lines are thus in high demand, supporting the rapid development of recombinant protein therapeutic products, where improvements in the development timeline and ease of generating high producing cell lines can contribute to the faster development of both innovative biopharmaceuticals and biosimilars.
Increasing expression of therapeutic glycoproteins produced on mammalian cell lines is an important step forward to reduce process development and manufacturing costs and therefore end product costs. The latter is enabled by reducing the scale of the final manufacturing process through savings in resources, materials, facility costs and scale-up time.
The STEP™ technology achieves high protein expression levels without the need for gene amplification and time-consuming rounds of cell sub-cloning by means of a highly stringent selection system which can be tailored to different types of protein such that maximum expression levels are always achieved. The result is a system that generates very high producing CHO cell lines from a limited but sufficient number (typically 20-30) of clones eliminating the burden of extensive screening.
In this webinar we will introduce, showing STEP™ ability to rapidly and easily generate cell lines with high yields of glycoprotein in the industrial workhorse CHO. The stability of expression and performance in bioreactors are addressed, as well as biological activity and quality of the proteins produced with the STEP™ technology. If you're interested in a novel potent expression system which can be developed in limited time and to overcome major challenges in the production of human therapeutic proteins, please register for this webinar.
Presented by
Femke Hoeksema,
Senior Scientist and Team Leader at Batavia Biosciences
Dr Hoeksema is a senior molecular biologist (University, Amsterdam) with a profound background in cell-oriented research and product development.
She has ample experience in investigation and development of techniques to increase expression levels by employment of expression enhancing DNA elements and adaptable stringent selection systems.
Dr Hoeksma developed several novel expression platforms for the production of recombinant proteins and antibody therapeutic molecules among which the leading STEP™ expression system.
Publications (selected):
The use of a stringent selection system allows the identification of DNA elements that augment gene expression. Mol Biotechnol 48, 19-29 (2011).
Placing the RPL32 promoter upstream of a second promoter results in a strongly increased number of stably transfected mammalian cell lines that display high protein expression levels. Biotechnol Res Int 2011, 492875 (2011).
Methods to create a stringent selection system for mammalian cell lines. Cytotechnology 63, 371-84 (2011).
Absence of an acute insulin response predicts onset of type 2 diabetes in a Caucasian population with impaired glucose tolerance. J Clin Endocrinol Metab 93, 2633-8 (2008).
